<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0028">
 <label>28</label>
 <element-citation publication-type="journal" id="sbref0028">
  <person-group person-group-type="author">
   <name>
    <surname>Chen</surname>
    <given-names>C.N.</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>C.P.C.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>K.K.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>W.C.</given-names>
   </name>
   <name>
    <surname>Hsieh</surname>
    <given-names>H.P.</given-names>
   </name>
   <name>
    <surname>Liang</surname>
    <given-names>P.H.</given-names>
   </name>
   <name>
    <surname>Hsu</surname>
    <given-names>T.A</given-names>
   </name>
  </person-group>
  <article-title>Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3,3â€²-digallate (TF3)</article-title>
  <source>Evid Based Complement Alternat Med</source>
  <volume>2</volume>
  <issue>2</issue>
  <year>2005</year>
  <fpage>209</fpage>
  <lpage>215</lpage>
  <pub-id pub-id-type="pmid">15937562</pub-id>
 </element-citation>
</ref>
